title: Oral paricalcitol.
abstract: black triangle An oral formulation of paricalcitol has been developed for the prevention and treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease.black triangle Paricalcitol is a synthetic vitamin D analog that binds to the vitamin D receptor inducing suppression of parathyroid hormone (PTH) secretion.black triangle Oral paricalcitol was significantly more effective than placebo in treating secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease. In a pooled analysis of three well designed, 24-week trials, two consecutive reductions from baseline in intact PTH levels of >/=30% were achieved by significantly more paricalcitol than placebo recipients (91% vs 13%).black triangle In addition, mean levels of the biochemical bone markers serum bone-specific alkaline phosphatase, serum osteocalcin, and urinary pyridinoline were reduced from baseline to a significantly greater extent with paricalcitol than with placebo, indicating a reduction in bone turnover.black triangle Oral paricalcitol was well tolerated; there was no significant difference between paricalcitol and placebo recipients in the incidence of hypercalcemia, hyperphosphatemia, or elevated calcium-phosphorus product.
authors.affiliation: Adis International Inc., Yardley, Pennsylvania, USA.
authors.forename: Emma D
authors.initials: ED
authors.lastname: Deeks
authors.forename: Katherine A
authors.initials: KA
authors.lastname: Lyseng-Williamson
mesh_terms: D002118:Calcium / Q000097:blood; D006801:Humans; D006934:Hypercalcemia; D006962:Hyperparathyroidism, Secondary / Q000097:blood; D007676:Kidney Failure, Chronic / Q000097:blood; D010281:Parathyroid Hormone / Q000097:blood; D014807:Vitamin D / Q000031:analogs & derivatives
chemical_list: D010281:Parathyroid Hormone; D014807:Vitamin D; D002118:Calcium